Inactive Instrument

The iQ Group Global Ltd.

Equities

IQG

AU0000080277

IQ Global : Continued Suspension - Failure to lodge Half Yearly Financial Statements- 31 December 20211

March 16, 2022 at 07:21 pm EDT

The IQ Group Global Limited - IQG ("the Company")

Conintued Suspension

The securities will remain under suspension as a result of the Company failing to lodge their Audit Reviewed Half Yearly Financial Statements, pursuant with Listing Rule 6.10.

All securities of The IQ Group Global Limited were originally placed under a Voluntary Suspension on 11 March 2022.

Details can be found at the following link:

https://www.nsx.com.au/ftp/news/021740628.PDF

The Securities of the Company will be reinstated to official quotation once it has satisfied its obligations according to the NSX Listing Rules.

For more information, please visit the NSX website www.nsx.com.au .

Yours sincerely,

Jane Thorley

Trading and Settlements

17 March 2022

Market Announcement

National Stock Exchange of Australia

Attachments

Original Link
Original Document
Permalink

Disclaimer

IQ Group Global Ltd. published this content on 17 March 2022 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 16 March 2022 23:20:08 UTC.

Latest news about The iQ Group Global Ltd.

Harvard Wyss Institute’S Erapid Sensor Technology Licensed to Antisoma Therapeutics to Facilitate Infectious and Immune Disease and Cancer Diagnostics	22-03-07	CI
The Iq Group Global Ltd. Reports Earnings Results for the Full Year Ended June 30, 2021	21-09-13	CI
The iQ Group Global Ltd. Auditor Raises 'Going Concern' Doubt	21-09-12	CI
The Iq Group Global Ltd. Reports Earnings Results for the Half Year Ended December 31, 2020	21-03-12	CI
The Iq Group Global Ltd. Reports Earnings Results for the Full Year Ended June 30, 2020	20-09-12	CI
The Iq Group Global Ltd. Reports Earnings Results for the Half Year Ended December 31, 2019	20-03-15	CI
IQnovate Ltd will Change its Name to The iQ Group Global Ltd	19-12-30	CI
Iqnovate Limited Reports Earnings Results for the Full Year Ended June 30, 2019	19-09-16	CI
Iqnovate Ltd. Reports Earnings Results for the Half Year Ended December 31, 2018	19-03-18	CI
IQnovate Limited Reports Audited Consolidated Earnings Results for the Year Ended June 30, 2018	18-09-29	CI
IQnovate Limited announced that it has received AUD 1.693483 million in funding a group of investors	18-09-18	CI
IQnovate Limited Reports Unaudited Consolidated Earnings Results for the Year Ended June 30, 2018	18-09-14	CI
IQnovate Limited announced that it has received AUD 0.60775 million in funding	18-08-05	CI
IQnovate Limited Reports Consolidated Earnings Results for the Half Year Ended December 31, 2017	18-03-16	CI
IQnovate Ltd. Reports Consolidated Earnings Results for the Year Ended June 30, 2017	17-10-19	CI
IQnovate Ltd. Reports Consolidated Earnings Results for the Half Year Ended December 31, 2016	17-03-16	CI
IQnovate Ltd. cancelled the acquisition of 50% stake in Emedia Creative Pty Ltd.	16-11-16	CI
IQnovate Ltd. Reports Consolidated Earnings Results for the Year Ended June 30, 2016	16-09-13	CI
IQN Extends and Expands its Strategic Alliance with Bartech Group	16-04-13	CI
IQnovate Ltd. Reports Consolidated Earnings Results for the Half Year Ended December 31, 2015	16-03-14	CI
IQnovate Ltd. agreed to acquire 50% stake in Emedia Creative Pty Ltd.	15-11-16	CI
IQnovate Ltd. announced that it expects to receive NZD 5 million in funding	15-03-10	CI
24,512,498 Ordinary Shares of IQnovate Ltd are subject to a Lock-Up Agreement Ending on 15-DEC-2013.	13-12-14	CI
IQnovate Ltd. announced that it has received AUD 2 million in funding.	13-03-12	CI
1,437,499 Ordinary Shares of IQnovate Ltd. are subject to a Lock-Up Agreement Ending on 15-DEC-2012.	12-12-14	CI

Chart The iQ Group Global Ltd.

Duration

Period

More charts

Company Profile

The IQ Group Global Ltd is an Australia-based life sciences and medical technology company. The Company is engaged in providing intellectual asset property management services, and integrated scientific advisory to the biopharmaceutical industry. It finds, funds and develops bioscience discoveries to create medical innovations and provide the fundamental basis for pharmaceuticals and devices that global populations of patients, hospitals and healthcare providers rely. Its platform technology, TEX Core is focused to develop compounds that are designed to be tumor localizing, well-tolerated, magnetic resonance imaging (MRI)-detectable in multiple solid tumors, including cancer cells that fail to respond to therapies. The Biosensor platform is a small, organic strip that puts accurate, timely diagnosis to patients and their primary health practitioners. The Company's platform is used for multiple diagnostic tests and translation medicine.

Sector

More about the company